SFRP4 and chronic kidney disease: Classical treatment strategies for vascular calcification have limited effect in CKD patients, which still have a very high cardiovascular mortality.(85, 86) Therefore, it is of high importance to further study whether the local expression of sclerostin, Dkk1, SFRP4, and activin A has a protective or detrimental role in uremic vasculopathy.